Abstract:366 Background: There is a paucity of data with respect to optimal management of metastatic renal cell carcinoma (mRCC) in older adults. Real world data may help close this knowledge gap and improve care for older patients with mRCC. Methods: The Canadian Kidney Cancer information system (CKCis) was utilized to identify patients with mRCC, categorizing them as either older (defined as age ≥75 years) or younger (age <75 years). We compared first line (1L) mRCC management strategies and treatment-related toxicities. Secondary outcomes were overall survival (OS) and time to treatment discontinuation (TTD). Chi-Square and Fisher’s Exact tests were used to compare groups, and survival outcomes were measured by Kaplan-Meier method. Cox’s proportional hazard ratio (HR) were reported by age adjusting for IMDC risk groups, histology, and Charlson Comorbidity Index (CCI) for OS and TTD. Results: 2576 patients were included (n=2203 <75 years old; n=373 ≥75 years old). Baseline demographics were comparable between groups, though older patients had more comorbidities (5+, 95% vs. 67%, p<0.0001) and more frequently had Karnofsky Performance Status <70% (18% vs. 13%, p=0.01). Older patients underwent metastasectomy less frequently (15% vs. 25%, p=0.0001) and were less likely to be enrolled in clinical trials (10% vs. 24%, p<0.0001). Older patients received 1L tyrosine kinase inhibitor (TKI) monotherapy more frequently (79% vs. 69%, p<0.0001) than immune checkpoint inhibitor (ICI)-based treatment, even when adjusted by year to account for changes in practice patterns in the post-ICI era (65% vs. 44%, p<0.0001). Amongst all patients, the TKI monotherapy most frequently prescribed was sunitinib, though older patients were more likely to receive pazopanib than younger patients ( p<0.0001). Amongst all patients who received 1L ICI-based treatment, there was no difference in the type of ICI regimen (i.e. doublet ICI versus ICI plus TKI) prescribed when compared by age ( p=0.61). Older patients did not experience more frequent treatment-related toxicities with ICI-based treatment. They did however experience more grade 3+ toxicity with TKI monotherapy. Older patients had shorter OS even when controlling for IMDC score, CCI and histology (HR 1.21, 95% CI 1.03-1.43, p=0.02). There was no difference in TTD by groups. Conclusions: Patients ≥75 years of age received TKI monotherapy more frequently than those <75 years of age, though when they received ICI-based regimens, they did not experience more treatment-related toxicities nor more dose modifications. Clinicians should individualize treatments for older patients not solely based on age, but after discussion of all available options in a patient-centered manner, considering comorbidities, disease burden, and patient preferences.

Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy

Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study

Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer

The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?

An Overview of the Roles of CDK4/6 Inhibitors in Metastatic Breast Cancer Elderly Patients

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery

Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer

Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients

Efficacy and safety of cyclin‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience

Real-World Data Analysis of CDK4/6 Inhibitor Therapy—A Patient-Centric Single Center Study

Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study

Overall Survival and Progression-Free Survival with Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy in Breast Cancer: an Updated Meta-Analysis of Randomized Controlled Trials

Systemic therapy for older patients with early breast cancer

Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).

Experience of treatment for breast cancer in women aged 70 years and elder

Metastasis patterns and prognosis of octogenarians with metastatic breast cancer: A large-cohort retrospective study

Recommendations for cyclin‐dependent kinase 4/6 inhibitor treatments in the context of co‐morbidity and drug interactions (Review)

Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice

Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment

An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy